Skip to content
303-321-2644
info@denverendocenter.com
799 E. Hampden Ave. Ste 525
Follow My Health Log-In
Home
About Us
Our Staff
Contact
Patient Info
Research Study Opportunities
Cadisegliatin a Adjunctive Therapy in Type 1 Diabetes
Efficacy, Safety, and Tolerability of IMVT 1402 for Graves’ Disease
Eversense Post Approval Study
Virtual Telemedicine
Schedule Appointment
New Patients
Metabolic and Genetic Endocrine Disorders
Prescription Refills
Pay a Bill
Insurance FAQ
Patient Privacy
Follow My Health
Portal Instructions
Resources
Research Study Opportunities
Cadisegliatin a Adjunctive Therapy in Type 1 Diabetes
Efficacy, Safety, and Tolerability of IMVT 1402 for Graves’ Disease
Eversense Post Approval Study
Home
About Us
Our Staff
Contact
Patient Info
Research Study Opportunities
Cadisegliatin a Adjunctive Therapy in Type 1 Diabetes
Efficacy, Safety, and Tolerability of IMVT 1402 for Graves’ Disease
Eversense Post Approval Study
Virtual Telemedicine
Schedule Appointment
New Patients
Metabolic and Genetic Endocrine Disorders
Prescription Refills
Pay a Bill
Insurance FAQ
Patient Privacy
Follow My Health
Portal Instructions
Resources
Research Study Opportunities
Cadisegliatin a Adjunctive Therapy in Type 1 Diabetes
Efficacy, Safety, and Tolerability of IMVT 1402 for Graves’ Disease
Eversense Post Approval Study
Research Study Opportunities
Cadisegliatin a Adjunctive Therapy in Type 1 Diabetes: A 52 Week Double Blind, Randomized, Placebo Controlled Phase 3 Study (CATT1)
Eversense® Continuous Glucose Monitor (CGM): A Post-Approval Study to Evaluate the Safety and Effectiveness of the Eversense® CGM System Used Non-Adjunctively (without another meter to compare)
Peripheral Diabetic Neuropathy: A Phase 2 Study to Evaluate the Safety and Efficiency of RTA901 in Patients with Diabetic Peripheral Neuropathic Pain
A Phase 2, Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of CT-868 Administered for 16 Weeks to Overweight and Obese Adult Participants with Type 1 Diabetes Mellitus
A Randomized, Double-Blind, Placebo Controlled, Phase 2b Study to Assess the Efficacy, Safety and Tolerability of IMVT-1402 as Treatment for Adult Patients with Graves’ Disease.
Call Us Today
Scroll to top